Menu Back to 2nd-DIA-Clinical-Operation-Monitoring-Workshop-in-Japan

Program Committee

  • Eri  Sekine
    Eri Sekine Head of Integrated Science & Operations Dept., Oncology Development and MA
    Novartis Pharma K.K., Japan
  • Midori  Fujikawa
    Midori Fujikawa Leader, Clinical Research Coordination Dept.
    Chugai Pharmaceutical Co., Ltd., Japan
  • Mitsuo  Hayashi, MSc
    Mitsuo Hayashi, MSc Director, Site Monitoring, Clinical Operation Area, Japan Development
    MSD K.K., Japan
  • Keiichi  Inaizumi
    Keiichi Inaizumi Study Lead, Clinical Operation
    Pfizer Japan Inc., Japan
  • Toshiko  Ishibashi
    Toshiko Ishibashi
    Abbvie GK, Japan
  • Mikiro  Kobayashi
    Mikiro Kobayashi Associate Manager, MDC-J Oncology, Development & Medical Affairs Div
    GlaxoSmithKline K.K., Japan
  • Hiroshi  Kosaku
    Hiroshi Kosaku Senior Corporate Officer, Business Incubation Unit
    CMIC Holdings Co., Ltd., Japan
  • Suzuko  Oikawa, RPh
    Suzuko Oikawa, RPh Director, Clinical Research
    Bristol-Myers Squibb, Japan
  • Satoshi  Saeki, MSc
    Satoshi Saeki, MSc Associate Director, Business Process Improvement & Innovation, QuILS
    Astellas Pharma Global Development, Inc., United States
  • Norio  Shimazaki
    Norio Shimazaki Senior Manager, CTA and STM Group, Regional Clinical Operation, Japan
    Bristol-Myers Squibb K.K., Japan
  • Kazumasa  Sugao
    Kazumasa Sugao Manager, Clinical Development Dept.
    Mitsubishi Tanabe Pharma Corporation, Japan
  • Kyoji  Tamanoi
    Kyoji Tamanoi Senior Clinical Trial Manager, Clinical Trial Management
    ICON Japan K.K., Japan
Load More